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Abstract
Introduction: Thrombotic microangiopathies constitute a heterogeneous group of diseases
characterised by microangiopathic haemolytic anaemia and thrombocytopaenia associated with
platelet aggregation in the microcirculation responsible for ischaemic manifestations. Classically,
thrombotic microangiopathies are described as encompassing two main syndromes: thrombotic
thrombocytopaenic purpura and the haemolytic-uraemic syndrome Many cases of idiopathic
thrombotic thrombocytopaenic purpura have, to date, been associated with severe ADAMTS13
metalloprotease deficiency while haemolytic uraemic syndrome usually occurs in the context of
normal protease activity. Oestrogens and factor V Leiden have rarely been implicated in the
pathogenesis of thrombotic microangiopathy.
Case presentation: We describe the case of a 17-year-old female with refractory thrombotic
thrombocytopaenic purpura. The patient was receiving a new generation of oral contraceptives for
dysmenorrhoea and had factor V Leiden. After undergoing prolonged and intense plasma exchange
therapy for 40 days and high dose oral corticosteroids therapy for 90 days, our patient recovered
fully.
Conclusion: Patients with refractory thrombotic thrombocytopaenic purpura should likely be
evaluated for congenital thrombophilic disorders and for ingestion of drugs that have been associated
with this rare form of thrombotic microangiopathy. Identification of these and as yet other unknown
genetic and/or acquired risk factors may lead to more judicious treatment approaches.
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Thrombotic microangiopathy (TMA) isa syndrome caused
by the development of hyaline thrombi in the micro-
vasculature resulting in thrombocytopaenia, microangio-
pathic haemolysis, and organ dysfunction [1]. TMA
includes: a) idiopathic thrombotic thrombocytopaenic
purpura (TTP) with or without severe ADAMTS13
deficiency, the latter being either congenital or acquired
due to an inhibitor; b) haemolytic uraemic syndrome
(HUS), diarrhoea associated(epidemic or sporadic) ordue
to complement factors and regulatory protein alterations
and c) secondary forms of TMA due to drugs, disseminated
malignancy, pregnancy or postpartum, haematopoietic
stem cell transplantation, autoimmune and other diseases
with overlapping clinical manifestations [1,2]. As there is
significant overlap these general categories are not
accepted by all authors in the field and today the
distinction between TTP and HUS probably describes
more a phenotype than an underlying pathophysiology.
Autoimmune inhibitors or genetic mutations of the von
Willebrand factor (VWF)-cleaving metalloprotease,
ADAMTS13, result in unusually large VWF multimers
that play a central role in the pathogenesis of TTP [1-4].
We present a case of a young woman with factor V Leiden
(FVL), who was prescribed a new generation contraceptive
and subsequently developed refractory TTP. Here we
discuss the possible role of FVL and/or oral contraceptives
in the development of TTP.
Case presentation
A 17-year-old Greek Caucasian female was admitted to our
department with weakness, new onset purpura, lethargy,
and mild fluctuating dysarthria over the last 24 hours. She
had recently followed a 10 days course of oral contra-
ceptives (0.02 mg ethinylestradiol and 0.075 mg gesto-
dene, Harmonette®) because of dysmenorrhoea. One year
earlier she reported having taken a similar compound for
the same reason, with no negative side effects. There was
no personal or family history of any gynaecological or
haematological disease.
Vital signs on admission were normal. Physical examina-
tion revealed a purpuric rash on both legs, while the liver
and spleen were not palpable. Laboratory findings on
presentation were remarkable for decreased haemoglobin,
101 g/L, marked thrombocytopaenia, 15×10
9/L, elevated
lactate dehydrogenase (LDH), 599 IU/L, and elevated
indirect bilirubin, 43 mmol/L. Coagulation tests were
normal. Haemolytic anaemia was confirmed by low
serum haptoglobin, <0.1 g/L and schistocytes on blood
smear compatible with TTP. Direct Coomb’s test was
negative, andclotting times were normal.Serum creatinine
and liver function tests were within normal limits. Lupus
anticoagulant, anti-dsDNA antibodies, as well as anti-
phospholipid antibodies were negative. Urinalysis
revealed haematuria of glomerular origin and trace of
protein.
She was immediately commenced on daily, single volume
(2.5 Lt) PE with fresh frozen plasma and 100 mg per day
oral prednisone. The platelet count and the LDH levels
normalized during the first 5 days of therapy. However, on
the 7
th day of daily plasmapheresis, the platelet count
decreased to 20×10
9/L, while LDH increased to 802 IU/L.
At that point twice-daily single volume PE was empirically
instituted with continuation of the corticosteroid therapy.
She responded slowly and recovered normal PLT levels 10
days after the beginning of intense plasmapheresis. On the
17
th day, the patient was weaned off plasmapheresis to
daily single volume PE, which resulted in a second drop of
PLTs to 100×10
9/L necessitating intensification of steroid
and PE treatment for a second time. She finally received
42 sessions of PE within 40 days and was weaned off
corticosteroids after 90 days of treatment.
Due to the prolonged course of her illness a screen for
genetic polymorphisms associated with thrombophilia
such as prothrombin G20210A, methylenetetrahydrofo-
late reductase (MTHFR) C677T andfactor V G1691A(FVL)
was requested, which only disclosed FVL heterozygous
status. On discharge she was advised to avoid oral
contraceptives. Four years later, TTP has not relapsed and
the patient remains in excellent clinical condition.
Discussion
Many drugs have been implicated as aetiological factors in
the pathophysiology of TMA. Oestrogens have been
associated with acquired idiopathic TTP, probably by
reducing prostacyclin production [5,6]. The particular
contraceptive that our patient received has not been
previously reported to cause TTP. Nevertheless it is
known that all natural and synthetic forms of oestrogens
can induce TTP, including contraceptives [5,7,8], tamox-
ifen [9], hormonal replacement preparations [10,11] or
increased production of oestrogens due to pregnancy or
post-partum [7,12]. Whether the concurrent use of
progesterone protects [5] or triggers the disease [13] is
controversial. Risk factors include positive family history,
concurrent toxin exposure and recently FVL [14]. Most
cases of oestrogen-related TTP seem to be idiosyncratic,
although re-exposure may cause relapses [5]. Our case
illustrates some of the characteristics of oestrogen related
TTP. Firstly, it occurred in a patient with previously
uncomplicated exposure, probably as a result of sensitiza-
tion of the immune system. Secondly, it was difficult to
manage, with refractoriness to plasmapheresis. Refractory
TTP is defined in the presence of persistent thrombocyto-
paenia (platelets < 150×10
9/L) or LDH elevation after a
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petechiae presented few days after the patient had received
contraceptives. However, the rarity of TTP in recipients of
oral oestrogens shows that exposure to oestrogens alone is
not sufficient for the development of the syndrome. Other
predisposing factors seem to be necessary which in our
case may have been FVL.
Inactivation of factor Va by activated protein C is impaired
in persons with FVL, and the increased prevalence of this
thrombophilic disorder in some patients with TMA is
consistent with studies that have implicated the thrombo-
modulin-protein C anticoagulant pathway in TMA. In a
study by Raife et al [14] the prevalence of FVL was
significantly increased among Caucasian TMA patients
with normal ADAMTS13 activity. Different results have
been reported by Krieg et al [4] who determined
ADAMTS13 activity and FVL carriership in 256 patients
presenting with various forms of TMA [4]. FVL was equally
common in patients with (6.8%) or without (8.6%)
decreased ADAMTS13 activity. However a higher preva-
lence of FVL (12.3%) was noticed in patients with HUS
and normal ADAMTS13 activity and therefore a contrib-
utory role of FVL could not be excluded in that study. A
recent registry study from South East England showed that
ADAMTS 13 activity levels were not significantly different
between idiopathic and secondary forms of TTP [3]. It is
also known that although ADAMTS13 levels are prognos-
tic of future relapses, the response rates to PE are similar
for idiopathic TTP with or without severe ADAMTS13
deficiency [1,2]. Therefore modifying factors may impact
on the severity of the disease and the response to
treatment. In a study by Wada et al [16] the plasma
protein C and antithrombin activities were markedly
reduced in TTP patients who died compared to those
who survived, suggesting that reduced plasma antithrom-
bin and protein C activities can be prognostic of outcome.
Therefore resistance to activated protein C due to FVL may
have a similar impact on outcomes. Most studies examin-
ing FVL prevalence in TTP were restricted to exploring a
possible pathogenetic role of FVL in patients with normal
ADAMTS13 activity, whereas they did not examine a
possible role on the severity of the clinical manifestations
and the response to treatment. We do not propose
performing FVL testing on every patient presenting with
acute TTP, but certainly in refractory cases such informa-
tion may help in avoiding early PE withdrawal and
consequent early relapses.
We did not measure the serum VWF-cleaving protease
activity in our patient, since the necessary assays were not
available. The diagnostic possibilities in our patient were
either idiopathic TTP or secondary TTP due to oral
contraceptives. In either case the possibility of having
ADAMTS13 deficiency would be high and therefore, the
differential diagnosis could not have been based on
ADAMTS13 levels. Moreover immediate clinical manage-
ment would not have been modified by the results of these
assays.
In conclusion, we present a case of refractory TTP in a
young woman who had been receiving a new generation
oral contraceptive and had concurrent FVL. We suggest
that patients with refractory TTP should likely be
investigated for ingestion of incriminating drugs and for
congenital thrombophilic disorders.
Identification of these and other possible applicable
constitutional or acquired risk factors could lead to more
individualized treatment approaches for patients with
TMA.
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